Dextenza in Pterygium Surgery

Michelle Rhee MD30 enrolled

Overview

DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with conjunctival autograft)

In patients who undergo pterygium surgery, eyes will be consecutively assigned to receive either DEXTENZA or topical prednisolone acetate 1%.15 eyes will receive a Dextenza insertion into both the upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then discontinued. 15 eyes will receive starting on postoperative day 1 topical prednisolone acetate 1% q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks then discontinued.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pterygium

Interventions

Dexamethasone Intracanalicular Insert, 0.4mgDRUG

To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.

Prednisolone Acetate 1%DRUG

To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible for inclusion in the study: • Age of at least 18 years with primary pterygia Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study: * Glaucoma * Ocular hypertension * Prior conjunctival surgery * Other uncontrolled ocular disease * Ocular surgery in either eye within 3 months * Use of eye drops other than postoperative medications and artificial tears

Locations (1)

New York Eye Specialists

New York, New York, United States